19

Dec2022
Mélanie Bourassa Forcier, Vice-Chairperson and Acting Chairperson of the Patented Medicine Prices Review Board (PMPRB), confirmed her resignation from the Board on Twitter on December 7, 2022. In her comment she indicated she is evaluating her legal obligations concerning whether she can share the reasons for her ... Read More

05

Dec2022
Last week the Patented Medicine Prices Review Board (PMPRB) presented its 2021 Annual Report  to Federal Health Minister Duclos in accordance with its reporting mandate outlined in sections 89 and 100 of the Patent Act. Key statistics reinforce concerns about Canada’s continued attractiveness for new medicine launch ... Read More

22

Nov2022
On October 6, 2022, the Patented Medicine Prices Review Board (PMPRB) published its Draft price regulatory Guidelines and has invited stakeholders to comment on its approach by December 5, 2022. PDCI strives to support timely transparency around public policy consultations and invites organizations and individuals who provided comments to ... Read More

13

Oct2022
On October 6, 2022, the Patented Medicine Prices Review Board (PMPRB) published its highly anticipated draft price regulatory Guidelines and has invited stakeholders to comment on its approach by December 5, 2022.While some aspects of these guidelines were anticipated, there are a number of new concerns and uncertainties ... Read More

06

Oct2022
The Patented Medicine Prices Review Board (PMPRB) today, Ocober 6, 2022, released its draft PMPRB Guidelines with a 60-day consultation period running until December 5, 2022. PMPRB maintains that final Guidelines will be issued by end of this year and previously indicated its intent for new Guidelines ... Read More

19

Aug2022
On August 18, 2022, PMPRB announced its decisions regarding Price Regulation of patented medicines during the ‘Interim Period’, between July 1, 2022 and when a final set of price regulatory guidelines is published. The PMPRB has decided to move forward with earlier proposals drafted June 30th, 2022, and ... Read More

20

Jul2022
On June 30, 2022, PMPRB issued a Notice and Comment which published its Proposed Interim Guidance and invited stakeholder comments until July 18, 2022. This Interim Guidance outlines PMPRB’s intentions for regulating the prices of patented medicines in the “interim period” between the coming-into-force date ... Read More

30

Jun2022
PMPRB Launches Consultation on its Proposed Interim Guidance Today, June 30, 2022, PMPRB published a proposed set of Interim Excessive Price Guidelines and has invited stakeholders to comment on the approach before July 18, 2022. This Interim Guidance outlines PMPRB’s intentions ... Read More

25

Apr2022
On April 14, 2022, Health Canada announced that the government will:  Proceed only with the proposed amendments to the Regulations pertaining to schedule of reference countries (the PMPRB11 replacing the PMPRB7).   Not proceed with new excessive price factors (cost effectiveness, market size, GDP) nor the reporting of third-party ... Read More

04

Apr2022
On March 31, 2022, PMPRB published its 2020 Annual Report on its website. Key statistics reinforce concerns about Canada’s continued attractiveness for new medicine investment and launch since drug pricing reform began in 2017. Statistical Highlights201820192020Total # of Patented Medicines for Human Use Reported ... Read More